These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9435868)

  • 1. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
    Porter LE; Nelson H; Ethem Gecim I; Rice DC; Thibault C; Chapoval AI
    Cancer Immunol Immunother; 1997; 45(3-4):180-3. PubMed ID: 9435868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of antitumor immunity after cure of pulmonary metastases, using staphylococcal enterotoxin B and bispecific antibody.
    Rice DC; Chapoval AI; Porter L; Nelson H
    Cancer Immunol Immunother; 1999 Aug; 48(5):230-8. PubMed ID: 10478639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of activated Vbeta8+ T cells disrupts bispecific antibody directed antitumor immunity.
    McConnell EJ; McLemore EC; Talac R; Joshi L; Nelson H
    J Surg Res; 2004 Nov; 122(1):103-12. PubMed ID: 15522322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
    Thibault C; Nelson H; Chapoval AI
    Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bispecific antibody 500A2 x 96.5 targets T-lymphocytes activated in vivo with staphylococcal enterotoxin B (SEB) against CL62 melanoma cells in vitro.
    Reid IM; Lundy JK; Donohue JH
    Surg Oncol; 1994 Oct; 3(5):279-85. PubMed ID: 7889221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application.
    Chapoval AI; Nelson H; Thibault C; Penna C; Dean P
    J Hematother; 1995 Dec; 4(6):571-7. PubMed ID: 8846018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
    Penna C; Dean PA; Nelson H
    Cancer Res; 1994 May; 54(10):2738-43. PubMed ID: 8168104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI; Nelson H; Thibault C
    J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody.
    Penna C; Dean PA; Nelson H
    Int J Cancer; 1996 Jan; 65(3):377-82. PubMed ID: 8575861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
    Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
    Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
    Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
    Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.
    Ruf P; Lindhofer H
    Blood; 2001 Oct; 98(8):2526-34. PubMed ID: 11588051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
    Belani R; Weiner GJ
    J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor.
    Newell KA; Ellenhorn JD; Bruce DS; Bluestone JA
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):1074-8. PubMed ID: 1899481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
    J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.